MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion

Dow Jones

06/03

By Katherine Hamilton

MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories.

The stock advanced 7% to $13.14 in pre-market trading Wednesday.

The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected.

Revenue growth was driven by a 22% increase in international sales.

MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems.

The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

June 03, 2026 09:34 ET (13:34 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2640907536"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640907536\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640907536?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640907536","market":"other","top_or_hot":-1,"title":"MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories. \n</p>\n<p>\n  The stock advanced 7% to $13.14 in pre-market trading Wednesday. \n</p>\n<p>\n  The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected. \n</p>\n<p>\n  Revenue growth was driven by a 22% increase in international sales. \n</p>\n<p>\n  MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems. \n</p>\n<p>\n  The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 09:34 ET (13:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-03 21:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories. \n</p>\n<p>\n  The stock advanced 7% to $13.14 in pre-market trading Wednesday. \n</p>\n<p>\n  The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected. \n</p>\n<p>\n  Revenue growth was driven by a 22% increase in international sales. \n</p>\n<p>\n  MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems. \n</p>\n<p>\n  The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 09:34 ET (13:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640907536","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640907536","pubTimestamp":1780493640,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories.The stock advanced 7% to $13.14 in pre-market trading Wednesday.The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected.Revenue growth was driven by a 22% increase in international sales.MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems.The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"MiniMed股价因第四季度销售额和雅培合作伙伴关系扩张而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories. \n\n\n  The stock advanced 7% to $13.14 in pre-market trading Wednesday. \n\n\n  The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected. \n\n\n  Revenue growth was driven by a 22% increase in international sales. \n\n\n  MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems. \n\n\n  The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 09:34 ET (13:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}